Share on StockTwits

BTG plc (LON:BTG)‘s stock had its “buy” rating reaffirmed by equities research analysts at Deutsche Bank in a research note issued to investors on Tuesday. They currently have a GBX 655 ($10.99) price objective on the stock. Deutsche Bank’s price objective suggests a potential upside of 7.73% from the company’s current price.

A number of other analysts have also recently weighed in on BTG. Analysts at Jefferies Group upgraded shares of BTG plc to a “buy” rating in a research note on Tuesday, July 29th. They now have a GBX 760 ($12.75) price target on the stock, up previously from GBX 525 ($8.81). Separately, analysts at N+1 Singer reiterated a “sell” rating on shares of BTG plc in a research note on Wednesday, July 16th. They now have a GBX 486 ($8.15) price target on the stock. Finally, analysts at Panmure Gordon reiterated a “buy” rating on shares of BTG plc in a research note on Wednesday, July 16th. They now have a GBX 670 ($11.24) price target on the stock. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 566.25 ($9.50).

Shares of BTG plc (LON:BTG) traded down 1.32% on Tuesday, hitting GBX 600.00. 424,705 shares of the company’s stock traded hands. BTG plc has a 52-week low of GBX 363.00 and a 52-week high of GBX 665.00. The stock’s 50-day moving average is GBX 618.6 and its 200-day moving average is GBX 583.8. The company’s market cap is £2.165 billion.

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with Analyst Ratings Network's FREE daily email newsletter.